ArcticZymes Technologies ASA (FRA:B4V) ROCE % : 0.66% (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is ArcticZymes Technologies ASA ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ArcticZymes Technologies ASA's annualized ROCE % for the quarter that ended in Dec. 2024 was 0.66%.

ArcticZymes Technologies ASA ROCE % Historical Data

The historical data trend for ArcticZymes Technologies ASA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArcticZymes Technologies ASA ROCE % Chart

ArcticZymes Technologies ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

32.06

26.15

15.23

4.91

-0.41

ArcticZymes Technologies ASA Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															0.48	0.94	1.40	-4.55	0.66

ArcticZymes Technologies ASA ROCE % Calculation

ArcticZymes Technologies ASA's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-0.113	/	( ( (29.495 - 1.878)	+	(29.301 - 1.409) )	/ 2 )
	=	-0.113	/	( (27.617	+	27.892)	/ 2 )
	=	-0.113	/	27.7545
	=	-0.41 %

ArcticZymes Technologies ASA's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	0.184	/	( ( (28.987 - 1.503)	+	(29.301 - 1.409) )	/ 2 )
	=	0.184	/	( ( 27.484	+	27.892 )	/ 2 )
	=	0.184	/	27.688
	=	0.66 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

ArcticZymes Technologies ASA (FRA:B4V) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ArcticZymes Technologies ASA ROCE % Related Terms

Thank you for viewing the detailed overview of ArcticZymes Technologies ASA's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

ArcticZymes Technologies ASA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArcticZymes Technologies ASA (FRA:B4V) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BIOTECO:Sweden AZT:Norway 0DRV:UK

Address

Sykehusveien 23, Tromso, NOR, 9294

Website

https://www.arcticzymes.com

ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Germany, Italy, France, and other countries.

ArcticZymes Technologies ASA Headlines

No Headlines